Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue Injury
A Multi-center, Prospective, Open-label, Controlled Study of the Pharmacokinetics and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue Injuries
A multi-center, prospective, open-label, controlled study of the pharmacokinetics and safety of the LicartTM topical system in pediatric and adult participants with minor soft tissue injuries. 150 male and female participants aged 6-16 and 18-45 with soft tissue injuries meeting the following criteria will be enrolled to evaluate the pharmacokinetics and safety of the Licart topical system in pediatric and adult participants with minor soft tissue injuries over a 14-day treatment course. The analgesic effects will also be evaluated of the topical system in pediatric and adult participants with minor soft tissue injuries over a 14-day treatment course. To collect principal investigator-reported global response to therapy.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Open-label, controlled study in pediatric and adult participants with minor soft tissue injuries. One-hundred fifty (150) participants between 6 and 11years old; 12 and 16 years old; and 18 and 45 years old will be enrolled, with equal numbers in each of the three age groups. The 50 adults enrolled will serve as the control. Participants will be seen by the principal investigator (PI) or designee at the clinical site, at entry and Visits 2 and 5 following the first topical system application, with the last visit scheduled on either Day 14 or the day after the participant experiences pain resolution. Visits 3 and 4 will be conducted via telehealth. At each study visit, adverse events (AEs) and concomitant medications will be recorded, local tolerability at the application site scored on a 7-point scale, and pain assessed by participants using the Wong-Baker FACES scale. Vital signs will be measured at the screening visit and Visits 2 and 5.
Participants will also assess pain twice daily (morning and evening) at home in the Participant Diary using the same Wong-Baker FACES scale. Blood samples will be obtained from each participant at Visit 2, 24 hours (± 1 hour) after initial topical system application at Visit 1, and at the time of study discontinuation (with a topical system in place) for determination of plasma diclofenac concentration and plasma activated partial thromboplastin time (aPTT). At the End-of-Study (EOS) Visit the principal investigator will provide an assessment of global response to therapy on a 5-point scale.
Participants will be asked to apply the Licart topical system once per day for a maximum of 14 days or until pain resolution, whichever occurs first.
This study will assess efficacy by the following assessments: Plasma diclofenac concentration, 24 hours (± 1 hour) after initial application (Visit 2) and EOS Visit; Pain score assessment by participant using the Wong-Baker FACES scale: every day (Participant Diary) and study visits on Visits 2, 3, 4 and 5; and Principal investigator assessment of global response to therapy on a 5-point scale.
This study will assess safety by the following assessments: Vital signs will be measured at the screening visit and Visit 2 and 5; AE reporting at each study visit; Local tolerability on a 7-point scale at Visits 2, 3, 4 and 5, or the day after pain resolution, with a topical system applied to the injured area; Plasma diclofenac concentration, 24 hours (±1 hour) after initial topical system application (Visit 2) and EOS Visit; and Plasma activated partial thromboplastin time (aPTT), 24 hours (±1 hour) after initial topical system application (Visit 2) and EOS Visit.
The primary endpoints of the study are: Diclofenac pharmacokinetic profile (Pediatric population vs Adult population; Two-sided 90% confidence interval (CI) <4 ng/mL); Local tolerability; AEs; and Activated partial thromboplastin time (aPTT).
The secondary endpoints of the study are: Participant-reported pain scores; Global response to therapy; and Vital signs.
All participants who receive at least one topical system will be subjected to classic safety and efficacy analyses. All participants who receive at least one topical system and have at least one blood draw to support determination of plasma diclofenac concentration will be subjected to the pharmacokinetic analysis. An evaluable participant population with adequate compliance and follow- up may also be analyzed.
Continuous variables will be presented as sample size, means, medians, standard deviations, range and 90% CI. Categorical variables will be presented as sample size, number of observations, percentages and exact 90% CI.
The participant population will be stratified by appropriate age categories and the effects of age may be analyzed using Analysis of Variance (ANOVA) or multiple regression methods.
Plasma diclofenac concentration in pediatric participants will be compared with those of adults using repeated measures mixed models (participants will have reached steady-state blood concentration by the time of the first blood draw).
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72212
- Applied Research Center
-
-
California
-
La Palma, California, Estados Unidos, 90623
- Atella Clinical Research, LLC.
-
-
Florida
-
DeLand, Florida, Estados Unidos, 32720
- University Clinical Research - Deland, LLC
-
Miami, Florida, Estados Unidos, 33155
- My Community Research, Inc.
-
Tamarac, Florida, Estados Unidos, 33321
- D & H Tamarac Research Centers, Inc.
-
-
Kentucky
-
Owensboro, Kentucky, Estados Unidos, 42303
- Research Integrity
-
-
New Mexico
-
Alamogordo, New Mexico, Estados Unidos, 88310
- Ascendant Research Clinic, LLC.
-
-
New York
-
The Bronx, New York, Estados Unidos, 10456
- Prime Global Research Inc.
-
-
South Carolina
-
Marion, South Carolina, Estados Unidos, 29571
- Ascendant Research Clinic, LLC.
-
-
Texas
-
Houston, Texas, Estados Unidos, 77057
- Next Level Urgent Care
-
Plano, Texas, Estados Unidos, 75093
- AIM Trials
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Willing to provide written informed consent;
- Male or female, 6-11 years old; 12-16 years old; or 18-45 years old;
- BMI <32kg/m2;
- Minor soft tissue injury within 96 hours of enrollment;
- Spontaneous pain of at least moderate intensity (i.e., pain of at least 6 on the Wong-Baker FACES® scale) according to the participant);
- Clinically significant injury according to the principal investigator;
- Willing and able to accommodate study requirements for data collection, including return for study Visits 2 and 5;
- Have access to high-speed internet, a computer, iPad, or android device for telehealth visits;
- Negative urine pregnancy test at inclusion for females of reproductive potential (started the menstrual cycle);
- For pediatric and adult females of reproductive potential (started the menstrual cycle): abstinence from sexual intercourse, or use of highly effective contraception for at least 30 days prior to screening, and agreement to use such a method during study participation and for three (3) days following the final topical system application;
- For pediatric and adult males of reproductive potential: abstinence from sexual intercourse, or use of condoms or other methods to ensure effective contraception with partner during study participation and for three (3) days following the final topical system application; and
- Able to read and speak English.
Exclusion Criteria:
- Major soft tissue injury (fractures are only exclusionary if the injury is stabilized with a device, e.g., a hard cast, that cannot be removed to allow a topical system to be applied to the injured area);
- Open skin lesion or any dermatological condition (e.g., skin infection, eczema) within the injured area;
- Injury involves the spine, digits, hands, or bottom of foot;
- Prior injury to the same site within the past 90 days;
- Three or more other prior injuries (minor or major) to the region in the past;
- Injury occurred more than 96 hours prior to study entry;
- Prior use of topical medication to involved area within 48 hours of study entry;
- Hypersensitivity disorders, including asthma or urticaria, but only if associated with exposure to aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) including diclofenac;
- Coagulation defects;
- Prior use of over the counter (OTC) analgesics or short-acting NSAIDs (ibuprofen, ketoprofen) within 6 hours of study entry (acetaminophen permitted up until the time of study entry);
- Prior use of narcotic analgesics within seven (7) days of study entry;
- Prior use of systemic anti-inflammatory steroidal drugs within 60 days of study entry;
- Prior use of long-acting NSAIDs such as piroxicam or naproxen since injury;
- Concomitant use of drugs which may be susceptible to interactions with diclofenac, or affect safety if used concomitantly (e.g., serotonin-selective reuptake inhibitors, lithium, digoxin, anticoagulants, antidiabetic agents, cyclosporin, methotrexate, quinolone antimicrobials, other NSAIDs, steroids and diuretics);
- Participants with mental, behavioral, or neurodevelopmental disorders for which the relevant disorder(s) prevent compliance with the protocol;
- Documented alcohol or drug abuse within 365 days of study entry;
- Documented nicotine dependence within 365 days of study entry;
- Current or prior history of severe cardiac, renal, or hepatic impairment or disease;
- Severe systemic diseases (e.g., cancer, severe acute infection);
- Any underlying disease or medication that severely compromises the participant's immune system;
- Current or prior history of any chronic pain disorder;
- Current or prior history of gastrointestinal bleeds or, ulcers;
- Females who are pregnant or breast feeding; or
- Participation in another clinical trial within 90 days of enrollment.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Investigational
LicartTM topical system application once per day for a maximum of 14 days or until pain resolution, whichever occurs first. |
The Licart™ (diclofenac epolamine) topical system was designed to deliver the nonsteroidal anti-inflammatory drug (NSAID) diclofenac to the site of a minor soft tissue injury through topical application. This investigational product (IP) is a 10 cm x 14 cm topical system comprised of an adhesive material containing 1.3% diclofenac epolamine that is bound to a non-woven polyester felt backing and covered with a polypropylene film release liner. The release liner is removed prior to topical application to the skin.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Plasma Diclofenac Concentration of Licart™ Topical System at V2 and V5/EOS.
Periodo de tiempo: 24 hours post-application (day 2 - V2), and Day 14 (V5) or one day after pain resolution (EOS)
|
The blood was withdrawn at Visit 2, 24 hours (± 1 hour) after initial topical system application on Visit 1, and the day following pain resolution or at the end of study (EOS - Day 14). Age-group based comparisons were performed using ANOVA. |
24 hours post-application (day 2 - V2), and Day 14 (V5) or one day after pain resolution (EOS)
|
|
Local Tolerability of the Licart™ Topical System as Assessed by a 7-point Scale.
Periodo de tiempo: 24 hours post-application (day 2 - V2), Day 4 (V3), Day 7 (V4), and Day 14 (V5) or EOS (the day after pain resolution)
|
Local tolerability of the Licart™ topical system was assessed by the PI, on a 7-point scale, ranging from 0 to 6 (6 = Redness with extension of effect beyond margin of contact site; 5 = Redness with weeping vesicles, blisters, or bullae; 4 = Redness with edema or papules; 3 = Intense redness; 2= Moderate redness, 1= Faint redness [not considered clinically relevant], 0 = none). The data of the participants with local tolerability score '0' are presented. Percentages are based on the total number of participants available at each study visit. Age-group based comparisons were performed using the Cochran-Mantel-Haenszel (CMH) test. CMH test p-value was not available for comparisons with less than two non-missing levels. Therefore, p-values were not available (NA) for V4 and V5/EOS for any of the group and also NA for age groups 6-11 vs 12-16 at V2 and age group 6-11 vs adult group at V3. |
24 hours post-application (day 2 - V2), Day 4 (V3), Day 7 (V4), and Day 14 (V5) or EOS (the day after pain resolution)
|
|
Number of Participants With Adverse Events as Assessed by the Study Team
Periodo de tiempo: 14 days after participant received first dose
|
Adverse events data were collected from the time the informed consent was obtained until the end of the study. It included exacerbation of a pre-existing medical condition, which increased in severity, frequency and/or duration (Information is available in Adverse Events section) |
14 days after participant received first dose
|
|
Pharmacokinetics of the Licart™ Topical System as Assessed by the Activated Partial Thromboplastin Time (aPTT)
Periodo de tiempo: 24 hours post-application (day 2 - V2), and Day 14 (V5) or one day after pain resolution (EOS)
|
Plasma aPTT at V2, assessed 24 hours (± 1 hour) after initial topical system application at V1 and at V5/EOS. aPTT was analyzed as raw aPTT value for adult groups while for both pediatric subgroups it was derived by subtracting 7.9 seconds from the raw values, i.e. the maximum difference between the normal values ranges for the two pediatric subgroups (6-11 years; 12-16 years) and the normal values range of adult participants, based on available relevant scientific literature. For each individual time point aPTT values were presented and summarized as means, SDs, and 90% CI of the means. Age-group based comparisons were performed using ANOVA (see Outcome Measure 5 for MMRM Model). |
24 hours post-application (day 2 - V2), and Day 14 (V5) or one day after pain resolution (EOS)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Study-visit Participants -Reported Pain Scores Assessed by the Wong-Baker FACES Pain Rating Scale
Periodo de tiempo: Day 1 (V1), 24 hours post-application (day 2 - V2), Day 4 (V3), Day 7 (V4), and Day 14 (V5) or one day after pain resolution (EOS)
|
Pain was assessed by the participant using the Wong-Baker FACES scale during each study visit at V1, V2, V3, V4, V5/EOS. The pain score options are as follows: 0 = No Hurt, 2 = Hurts Little Bit, 4 =Hurts Little More, 6 = Hurts Even More, 8 =Hurts Whole Lot, 10 = Hurts Worst. The lower the score, the better the outcome; the higher the score, the worse the outcome. Age-group based comparisons were performed using ANOVA. |
Day 1 (V1), 24 hours post-application (day 2 - V2), Day 4 (V3), Day 7 (V4), and Day 14 (V5) or one day after pain resolution (EOS)
|
|
Global Response to Licart™ Topical System as Assessed by the Global Response to Therapy Investigator-reported Questionnaire
Periodo de tiempo: on Day 14 (V5) or one day after pain resolution (EOS)
|
Global response to therapy was assessed by the PI or designee on a 5-point scale (1= No clinical improvement in pain intensity and/or functional performance, 2= Slight clinical improvement in pain intensity and/or functional performance, 3= Moderate clinical improvement in pain intensity and/or functional performance, 4= Marked clinical improvement in pain intensity and/or functional performance, 5= Restoration of normal functional performance in the absence of any pain). Age-group based comparisons were performed using the Cochran- Mantel-Haenszel (CMH) test. 90% CI was used as measure of dispersion. |
on Day 14 (V5) or one day after pain resolution (EOS)
|
|
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Periodo de tiempo: 24 hours post-application (Day 2 - V2), and Day 14 (V5) or one day after pain resolution (EOS)
|
Vital sign included SBP and DBP. Vital Sign summarized as change from Baseline by visit at Visit 2 and V5/EOS. Values at screening were considered as Baseline value. Change from Baseline was calculated as visit value - value at screening. |
24 hours post-application (Day 2 - V2), and Day 14 (V5) or one day after pain resolution (EOS)
|
|
Change From Baseline in Heart Rate (HR)
Periodo de tiempo: 24 hours post-application (day 2 - V2), and Day 14 (V5) or one day after pain resolution (EOS)
|
Vital sign included HR. Vital Sign summarized as change from Baseline by visit at Visit 2 and V5/EOS. Values at screening were considered as Baseline value. Change from Baseline was calculated as visit value - value at screening. |
24 hours post-application (day 2 - V2), and Day 14 (V5) or one day after pain resolution (EOS)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Giuseppe Mautone, MD, IBSA R&D Scientific Affairs
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 18US-FHp04
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .